SCHEMBL2132913

SCHEMBL2132913

CCOC(=O)C(C)Nc1c(Br)cc(F)cc1[N+](=O)[O-]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MAPT P10636 6/20 0.40
SMN1; SMN2 Q16637 5/20 0.38
MAPK1 P28482 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
LMNA P02545 2/20 0.37
GALR2 O43603 1/20 0.37
MITF O75030 1/20 0.37
POLB P06746 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HPGD P15428 1/20 0.37
XBP1 P17861 1/20 0.37
CCR6 P51684 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KMT2A Q03164 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2610870 0.78 MAPT (0.49) ALDH1A1L3MBTL1MAPTSMN1; SMN2MAPK1
SCHEMBL17673169 0.78 ALDH1A1 (0.43) ALDH1A1L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL19518273 0.78 ALDH1A1 (0.43) ALDH1A1L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL2176401 0.78 MAPT (0.49) ALDH1A1L3MBTL1MAPTSMN1; SMN2MAPK1
SCHEMBL31607286 0.75 ALDH1A1 (0.40) ALDH1A1L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL31607348 0.75 ALDH1A1 (0.40) ALDH1A1L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL25380351 0.74 ALDH1A1 (0.38) ALDH1A1L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL31474310 0.73 KMT2A (0.47) ALDH1A1MAPTSMN1; SMN2POLBHPGD
SCHEMBL29215568 0.73 KMT2A (0.47) ALDH1A1MAPTSMN1; SMN2POLBHPGD
SCHEMBL25310326 0.72 ALDH1A1 (0.38) ALDH1A1L3MBTL1CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493506-B2 Macrocyclic hepatitis C serine protease inhibitors ABBVIE INC. (US) 2016-11-15 US disclosed
US-20140287992-A1 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBOTT LABORATORIES 2014-09-25 US disclosed
US-8748374-B2 Macrocyclic hepatitis C serine protease inhibitors ABBVIE, INC. (US) 2014-06-10 US disclosed
EP-2576564-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS Abbvie Inc. (US) 2013-04-10 EP disclosed
US-20120101031-A1 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2012-04-26 US disclosed
WO-2011156337-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBOTT LABORATORIES (US) 2011-12-15 WO disclosed
WO-2011156337-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBOTT LABORATORIES (US) 2011-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101031-A1 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS TMPRSS15, PRSS1, SPINT2 ALDH1A1 1994/4885L3MBTL1 3125/4885CYP1A2 693/4885
US-20140287992-A1 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS TMPRSS15, PRSS1, SPINT2 ALDH1A1 1994/4885L3MBTL1 3125/4885CYP1A2 693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.